BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 26276272)

  • 1. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Miyamoto K; Aiba T; Arihiro S; Watanabe M; Kokubo Y; Ishibashi K; Hirose S; Wada M; Nakajima I; Okamura H; Noda T; Nagatsuka K; Noguchi T; Anzai T; Yasuda S; Ogawa H; Kamakura S; Shimizu W; Miyamoto Y; Toyoda K; Kusano K
    Heart Vessels; 2016 Aug; 31(8):1327-36. PubMed ID: 26276272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHA
    Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis.
    Senoo K; Lane DA; Lip GY
    Int J Cardiol; 2015 Feb; 181():247-54. PubMed ID: 25528530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
    Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the Outcomes of Acute Ischemic Stroke with Rheumatic Heart Disease: The Values of CHADS2, CHA2DS2-VASc, and HAS-BLED Scores.
    Liu J; Wang D; Tan G; Yuan R; Xu M; Xiong Y; Liu M
    J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):722-6. PubMed ID: 26774873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy.
    Komatsu T; Sato Y; Ozawa M; Kunugita F; Yoshizawa R; Morino Y; Nakamura M
    Int Heart J; 2014; 55(2):119-25. PubMed ID: 24632957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis.
    Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Liao JN; Chen TJ; Lip GY; Chen SA
    Heart Rhythm; 2014 Oct; 11(10):1752-9. PubMed ID: 24952148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
    Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.